A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors

NCT06001580 | Completed Phase 1

• 1 other identifier: BR101-I
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a phase Ia study of single drug BR101 for Advanced solid tumor. The main purpose of this study is to Evaluate the safety and tolerability of BR101monotherapy (single dose and multiple doses) in Subjects with Advanced Solid Tumors and determine the MTD if possible, and determine the RP2D. The secondary purpose of this study is to explore the Pharmacokinetics, Immunogenicity, Antitumor Activity of BR101 monotherapy (single dose and multiple doses) in Subjects with Advanced Solid Tumors

Conditions

Advanced Solid Tumor

Outcome Measures

Primary Outcomes (1)

• Safety, Tolerability,RP2D

  The incidence and severity of various adverse events of DLT, evaluated per NCI CTCAE 5.0 standard, abnormal physical examination, vital signs, laboratory examination, 12-guided ECG, etc.; maximum tolerated dose (MTD)(if possible). Recommended Phase II clinical trial dose

  up to 91 days after the last administration

Secondary Outcomes (13)

• Cmax

  From screening to 31 days after the last administration

• Tmax

  From screening to 31 days after the last administration

• AUC0-last

  From screening to 31 days after the last administration

• AUC0-tau

  From screening to 31 days after the last administration

• Cmin

  From screening to 31 days after the last administration

Study Arms (1)

BR101

EXPERIMENTAL

Drug: BR101

Interventions

BR101 DRUG

BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study

BR101

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Patients who voluntarily sign the informed consent form with an understanding of the nature, purpose and procedures of the trial, and can comply the protocol;
• \. Males and females with an age of or above 18 years;
• \. Patients with advanced or metastatic solid tumors diagnosed by pathological histology and / or cytology (cell wax only) who are unable for radical surgical resection, or who have failed to standard treatment or who have been intolerant to standard treatment (disease progression, or intolerant to chemotherapy, targeted therapy, etc.), or who lack effective treatment;
• \. At least one measurable lesion according to RECIST V1.1;
• \. ECOG score ≤ 1;
• \. A recovery of previous treatment releated toxic reactions (except for the residual hair loss effect) to or under Grade 1 (according to CTCAE v 5.0) and a complete recovery of the immune-related adverse effects if the patients received anti-tumor treatment before;
• \. Sufficient organ and bone marrow function;
• \. The expected survival above 12 weeks;
• \. Blood HCG test of females with a reproductive potential should be negative;
• \. Fertile men and women must use a highly effective contraceptive methods, and continue the birth control for six months after the last dose.

You may not qualify if:

• \. An current active autoimmune disease or history;
• \. A history of primary immunodeficiency;
• \. An current interstitial lung disease or history (except local interstitial lung disease induced by radiotherapy);
• \. An active tuberculosis or history;
• \. Any active infection that requires systemic treatment through intravenous infusion within 14 days before first dose;
• \. Two or more primary tumors (excluding cured cervical in situ carcinoma, basal cell carcinoma or squamous cell skin cancer, and other tumors that have been treated and stable for more than 5 years);
• \. Symptomatic or untreated metastasis in brain or other central nervous system. However, patients with CNS matastasis that has been completed removed and/or be stable or relieved after radiotherapy can be enrolled;
• \. Uncontrollable pleural fluid, ascites, or pericardial effusion assesed by the investigator;
• \. Patients with any of the following heart diseases: any grade of heart failure assesed by NYHA, severe cardiac arrhythmias requiring treatment, Unstable angina pectoris，myocardial infarction occurred within 3 months before the first dose, QTc≥480 ms, hypertension that cannot in good control, receiving PTCA or CABG within 6 months before the first dose;
• \. Patients received anti-tumor therapy or participated in other clinical studies and used other test drugs 28 days before the first dose; Patients received the traditional Chinese medicine within 7 days before the first dose;
• \. A history of psychopathy;
• \. A history of major surgery or radiotherapy within 28 days before the first dose or expecting to operate a major surgery during the trial, a history of therapeutic radioactive agents within 56 days prior to the first dose;
• \. A history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
• \. Patients who have a bleeding tendency or are receiving thrombolytic or anticoagulant therapy;
• \. Patients who had been vaccinated within 28 days before the first dose or intend to be vaccinated during the trial;

Sponsors & Collaborators

• BioRay Pharmaceutical Co., Ltd.: lead

Study Sites (1)

The Second Affiliated Hospital of Zhejiang University Medical College

Hangzhou, Zhejiang, 310052, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 4, 2023
• First Posted: August 21, 2023
• Study Start: August 11, 2021
• Primary Completion: October 27, 2023
• Study Completion: February 7, 2024
• Last Updated: November 21, 2025

Record last verified: 2025-11

Locations

CN (1)